Filing alleges revised Schedule A after signing and conflicting revocation terms
Pfizer’s RIF and severance practices face scrutiny in a Dec. 8 New Jersey filing by a former physician challenging OWBPA disclosures and retaliation.
A newly filed case in the United States District Court for the District of New Jersey focuses on reductions-in-force, severance agreements and age-bias safeguards. The filing, dated December 8, 2025, comes from former Pfizer physician Alejandra Nieto, M.D., who alleges nearly a decade of escalating retaliation after raising internal concerns about patient safety, scientific and data integrity, and regulatory compliance.
For HR leaders, the core of the case is the company’s 2023 reduction-in-force and the disclosures attached to the severance agreement. According to the filing, Pfizer informed Nieto in late 2023 that her longstanding remote role would shift to in-person work. Within weeks, she was told her position was eliminated in a RIF. She alleges the company declined to share its ranking criteria, scores, comparators or methodology and did not consider her for other roles despite her background.
The most consequential allegation centers on the Older Workers Benefit Protection Act, which sets conditions for waiving age-discrimination claims in group layoffs. Nieto says she signed a Separation Agreement on February 12, 2024 after being told the required disclosures—including a Schedule A listing the decisional unit, job titles, and ages of those selected and not selected—were complete and accurate. Five days later, on February 17, 2024, she received a revised Schedule A that, she alleges, added or corrected information about individuals in the decisional unit, including ages and titles. She contends the company did not restart the required consideration and revocation periods after issuing the corrected disclosure.
The filing also describes conflicting signals about timing. It alleges the revised Schedule A stated she had 60 days to consider and 7 days to revoke—impossible, she says, because she had already signed. Separate written communications allegedly referred to a “52-day” revocation period that did not match the 7-day clause in the agreement. Nieto further alleges a December 15, 2023 document labeled as part of the RIF package was incomplete and that the original disclosure was not provided upon request.
On the age-discrimination front, the filing says Nieto, then 52, and one colleague in their early forties were the only people selected for termination in the relevant decisional unit, while retained employees ranged from fifty-seven to eighty-one years of age. The pleading ties those allegations to a broader timeline: protected disclosures beginning in 2014; a 2019 demotion from Global Clinical Lead to a Clinician role; and progressive exclusion from governance forums, meetings and strategic work. It also alleges post-separation retaliation, including continued reliance on an allegedly invalid waiver in a submission to the New York State Division of Human Rights.
Nieto seeks a declaration that the age waiver is invalid, reinstatement or front pay, back pay and lost benefits, compensatory, liquidated and punitive damages, injunctive relief, attorneys’ fees and costs, and interest. The matter is at an early stage, the allegations are unproven, and there has been no determination on the merits.
For HR professionals managing complex RIFs and severance programs, the filing underscores the importance of accurate decisional-unit disclosures, clear and consistent revocation timelines, and transparent documentation—especially when processes shift from remote arrangements to in-person roles and then to layoffs.
